Study on the expression and mechanism of plasma microRNA-21 in patients with ischemic cardiomyopathy.
To investigate the expression and mechanism of plasma microRNA-21 in patients with ischemic cardiomyopathy (ICM). 56 cases of ICM patients were selected in our hospital from February 2010 to March 2016 as the observation group, and 60 cases of healthy patients were selected as control group. Real-time quantitative polymerase chain reaction (qRT-PCR) was used to detect the expression of microRNA-21 in two groups. Then, differences of the total cholesterol (TC), triglycerides (TG), left ventricular ejection fraction (LVEF), high and low density lipoprotein cholesterol (HDL-C, LDL-C), left ventricular end-diastolic volume (LVEDV), N terminal B type brain natriuretic peptide (NT-proBNP) and other clinical indicators of the two groups, were compared. The correlation between the plasma microRNA-21 level and the clinical indices was analyzed, and the value of microRNA-21 in the diagnosis and treatment of ICM was evaluated. The levels of LDL-C, HDL-C and LVEF in the observation group were lower than those in the control group (p<0.05). Plasma microRNA-21, TG, NT-proBNP and LVEDV were higher than those in the control group; the difference was statistically significant (p<0.05). Logistic regression analysis showed that the plasma microRNA-21 level was positively correlated with NT-proBNP and LVEDV (p<0.05). The expression of microRNA-21 in plasma of patients with ICM was significantly increased. And the expression of micro RNA-21 in plasma was positively correlated with NT-proBNP and LVEDV. Through the ventricular remodeling in ICM patients, it can be used as a new target for the diagnosis and treatment of ICM and a new biomarker for risk assessment.